Alternate methods for assessing absorption, metabolism, and routes of elimination

Preclinical Drug Development

Volumn , Issue , 2005, Pages 303-347

  Bullock, Peter ^a  

^a PURDUE PHARMA L P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34748817038     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (120)

1. Prentis RA, Lis Y, Walker SR. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 1988; 25:387-396.
2. Kuhlmann J. Drug research: from the idea to the product. Intl J Clin Pharmacol Ther 1997; 35(12):541-552.
3. Kubinyi H. Strategies and recent technologies in drug discovery. Pharmazie 1995; 50:647-662.
4. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Economics 2003; 22:151-185.
5. Lipper RA. E pluribus product. Mod Drug Disc 1999; Jan/Feb:55-60.
6. Hardin JH, Smietana FR. Automating combinatorial chemistry: a primer on benchtop robotic systems. Mol Divers 1995; 1:270.
7. Myers PL. Will combinatorial chemistry deliver real medicines? Pharmaceut Biotechnol 1997; 8(6):701-707.
8. Lipinski CA, Lombardo F, Dominy BW, Feeny PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23:3-25.
9. Testa B, Carrupt P, Gaillard P, Billbois F, Weber P. Lipophilicity in molecular modelling. Pharm Res 1997; 13:335-343.
10. Purcell WP, Bass GE, Clayton JM. Strategy to Drug Design: a Guide to Biological Activity. New York: Wiley Interscience, 1973.
11. Navia MA, Chaturvedi PR. Design principles for orally bioavailable drugs. Drug Dev Today 1996; 1:179-189.
12. Hansch C, Leo A. Substituent Constants for Correlation in Chemistry and Biology. New York: Wiley, 1979.
13. Henry D, Block JH, Anderson JL, Carlson GR. The use of high-pressure liquid chromatography for quantitative structure-activity relationship studies of sulfonamides and barbiturates. J Med Chem 1976; 19:619-626.
14. Garst JE, Wilson WC. Accurate, wide-range, automated, high-performance liquid chromatographic method for the estimation of octanol/water partition coefficients I: effect of chromatographic conditions and procedure variables on accuracy and reproducibility of the method. J Pharm Sci 1984; 73(11): 1616-1623.
15. Pjura WJ, Kleinfeld AM, Karnovsky MJ. Partition of fatty acids and fluorescent fatty acids into membranes. Biochemistry 1984; 23:2039-2043.
16. Katz YJ, Diamond JM. Thermodynamic constants for non-electrolyte partition between dimyristol lecithin and water. J Membr Biol 1974; 17(2):101-120.
17. Ong S, Liu H, Qiu X, Bhat G, Pidgeon C. Membrane partition coefficients chromatographically measured using immobilized artificial membrane surfaces. Anal Chem 1995; 67:755-762.
18. Ong S, Liu H, Pidgeon C. Immobilized-artificial-membrane chromatography: measurements of membrane partition coefficient and predicting drug membrane permeability. J Chromatogr A 1996; 728:113-128.
19. Barbato F, La Rotonda M, Quaglia F. Interactions of nonsteroidal antiinflammatory drugs with phopholipids: comparison between octanol/ buffer partition coefficients and chromatographic indexes on immobilized artificial membranes. J Pharm Sci 1997; 86(2):225-229.
20. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 1998; 41(7):1007-1010.
21. Buchwald P, Bodor N. Octanol-water partition: searching for predictive models. Curr Med Chem 1998; 5:353-380.
22. Zhang WZ, Cosolo W, Zalcberg J. In vitro binding of MX2 (KRN8602) and epirubicin to human plasma protein. Pharmacol 1997; 55(6):279-284.
23. Borga O, Borga B. Serum protein binding of nonsteroidal antiinflammatory drugs: a comparative study. J Pharmacokinet Biopharm 1997; 25(1):63-77.
24. Hage DS, Tweed SA. Recent advances in chromatographic and electrophoretic methods for the study of drug-protein interactions. J Chromatogr B Biomed Sci Appl 1997; 699(1-2):499-525.
25. Bertucci C, Wainer IW. Improved chromatographic performance of a modified human albumin based stationary phase. Chirality 1997; 9(4):335-340.
26. Russeva VN, Zhivkova ZD. Protein binding of some nonsteroidal anti-inflammatory drugs studied by high-performance liquid affinity chromatography. Int J Pharm 1999; 180(1):69-74.
27. Koeplinger KA, Zhao Z. Chromatographic measurement of drug-protein interaction: determination of HIV protease inhibitor-serum albumin association. Anal Biochem 1996; 242(1):66-73.
28. Busch MH, Carels LB, Boelens HF, Kraak JC, Poppe H. Comparison of five methods for the study of drug-protetin binding in affinity capillary electrophoresis. J Chromatogr A 1997; 777(2):311-328.
29. Camenisch G, Alsenz J, van de Waterbeemd H, Folkers G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci 1998; 6:313-319.
30. Yazdanian M, Glynn SL, Wright JL, Hawi A. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharmaceut Res 1998; 15(9):1490-1494.
31. Camenisch G, Folkers G, van de Waterbeemd H. Shapes of membrane permeability-lipophilicity curves: extension of theoretical models with an aqueous pore pathway. Eur J Pharma Sci 1998; 6:321-329.
32. Martin YC. A practioner's perspective of the role of quantitative structure- activity analysis in medicinal chemistry. J Med Chem 1981; 24:229-237.
33. Wils P, Warnery A, Phung-ba V, Legrain S, Scherman D. High lipophilicity decreases drug transport across intestinal epithelial cells. J Pharmacol and Exper Ther 1994; 269(2):654-658.
34. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a pharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12:413-420.
35. Pade V, Stavchansky S. Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci 1998; 87(12):1604-1607.
36. Abraham MH, Chada SH, Whiting GS, Mitchell RC. Hydrogen bonding 32: an analysis of water-octanol and water alkane partitioning and the delta log P of Seiler. J Pharm Sci 1994; 83:1085-1100.
37. Jackson MJ. Johnson LR, ed. In: Physiology of the Gastrointestinal Tract. 2nd ed. Chapter 59. New York: Raven, 1987:1597-1621.
38. Stewart BH, Chan OH, Lu RH, Ryner EL, Schmid HL, Hamilton HW, Steinbaugh BA, Taylor MD. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans. Pharm Res 1995; 12(5):693-699.
39. Rousset M, Chevalier G, Rousset JP, Dussaulx E, Zweibaum A. Presence and cell growth-related variations of glycogen in human colorectal adenocarcinoma call lines in culture. Cancer Res 1979; 39:531-534.
40. Pinto M, Robine-Leon S, Appay MD, Kedlinger M, Triadou N, Dussaulx E, Lacroix B, Simon-Assmann P, Haffen K, Fogh J, Zweibaum A. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol Cell 1983; 47:323-330.
41. Grasset E, Pinto M, Dussaulx E, Zweibaum A, Desjeux JF. Epithelial properties of human colonic carcinoma cell line Caco-2: electrical parameters. Am J Physiol 1984; 247:C260-C267.
42. Hilgers AR, Conradi RA, Burton PS. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res 1990; 7(9):902-910.
43. Hildago IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989; 96(3):736-749.
44. Artursson P, Karlson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175(3):880-885.
45. Walter E, Janich S, Roessler BJ, Hilfinger JM, Amidon G. HT29-MTX/Caco-2 co-cultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci 1996; 85(10):1070-1076.
46. Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact of myth. Pharm Sci 1997; 14(6):763-766.
47. Caro I, Boulenc X, Rousset M, Meunier V, Bourrie M, Julian B, Joyeaux H, Roques C, Berger Y, Zweibaum A, Fabre G. Characterisation of a newly isolated Caco-2 clone (TC-7), as a model of transport processes and biotransformation of drugs. Int J Pharm 1995; 116:147-158.
48. Gres MC, Julian B, Bourrie M, Meunier V, Roques C, Berger M, Boulenc X, Berger Y, Fabre G. Correlation between oral drug absorption in humans and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line. Pharm Res 1998; 15(5):726-733.
49. Chong S. Evaluation of Biocoat intestinal epithelium differentiation environment as an absorption screening model with improved productivity. Pharm Res 1995; 13:S240-S245.
50. Cho MJ, Thompson DP, Cramer CT, Vidmar TJ, Scieszka JF. The Madin-Darby canine kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier. Pharm Res 1989; 6:71-77.
51. Rinaldi G, Seneci P, Guba W, Islam K, Sambuy Y. Transport of the antimicrobial agent oxazolidin-2-one and derivative across intestinal (Caco-2) and renal (MDCK) epithelial cell lines. Antimicrob Agents Chemother 1996; 40:652-658.
52. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick SE, Grove JR. MDCK (Madin-Darby Canine Kidney) cells: a tool for membrane permeability screening. J Pharm Sci 1999; 88(1):28-33.
53. Taylor EW, Gibbons JA, Braeckman RA. Intestinal absorption screening of mixtures from combinatorial libraries in the Caco-2 model. Pharm Res 1997; 14(5):572-577.
54. Caldwell GW, Easlick EM, Gunnet J, Masucci JA, Demarest K. In vitro permeability of eight B-blockers through Caco-2 monolayers utilizing liquid chromatography/electrospray ionization mass spectrometry. J Mass Spectrom 1998; 33:607-614.
55. Stevenson CL, Augustijns PA, Hendren RW. Use of Caco-2 cells and LC-MS to screen a peptide combinatorial library for permeable structures. Int J Pharma 1999; 177:103-115.
56. Tiberghein F, Loor. Ranking of P-glycoprotein substrates and inhibitors by calcein-Am fluorometry assay. Anticancer Drugs 1996; 7:568-578.
57. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 1992; 267: 4854-4858.
58. Urbatsch IL, al SM, Senior AE. Characterization of the ATPase activity of purified Chinese Hampster P-glycoprotein. Biochemistry 1994; 33:7069-7076.
59. Wang E, Casciano CN, Clement RP, Johnson WW. Two transport binding sites of P-glycoprotein are unequal yet contingent: initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependance. Biochimica et Biophysica Acta 2000; 1481:63-74.
60. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2001; 299:620-628.
61. Eylan GD, Regev R, Oren G, Hurwitz CD, Assaraf YG. Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug resistant cells is determined by their passive transmembrane movement rate. Eur J Biochem 1997; 248:104-112.
62. Schwab D, Fischer H, Tabatabei A, Poli S, Huwyler J. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem 2003; 46:1716-1725.
63. Litman T, Zeuthen T, Skovsgaard T, Stein WD. Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. Biochem Biophys Acta 1997; 1361:159-168.
64. Pauli-Magnus C, von Richter O, Zeigler A, Metang T, Eichelbaum M, Fromm MF. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther 2000; 293:376-382.
65. White RE. Short and long-term projections about the use of drug metabolism in drug discovery. Drug Metab Dispos 1998; 26(12):1213-1216.
66. Wrighton SA, Ring BJ, VandenBranden M. The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. Toxicol Pathol 1995; 23(2):199-208.
67. Parkinson A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 1996; 24(1):45-57.
68. Lamberg TS, Kivisto KT, Neuvonen PJ. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. 1998; 63(6): 640-645.
69. Lin JH, Lu AYH. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997; 49(4):403-449.
70. Eddershaw PJ, Dickens M. Advances in in vitro drug metabolism screening. Pharm Sci Technol Today 1999; 2(1):13-19.
71. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastal P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283(1): 46-58.
72. Rane A, Wilkinson GR, Shand DG. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther 1977; 200(2):420-424.
73. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47(9):1469-1479.
74. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283(1):46-58.
75. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 1997; 73(2):147-171.
76. Houston JB, Carlile DJ. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 1997; 29(4):891-922.
77. Chiba M, Fujita S, Suzuki T. Pharmacokinetic correlation between in vitro hepatic microsomal enzyme kinetics and in vivo metabolism of imipramine and desipramine in rats. J Pharm Sci 1990; 79:281-287.
78. Obach RS. The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metab Dispos 1996; 24(10):1047-1049.
79. Obach RS. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 1997; 25(12): 1359-1369.
80. DiFrancesco C, Bickel MH. Membrane lipids as intracellular binders of chlor-promazine and related drugs. Chem Biol Interact 1977; 16:335-346.
81. Ashforth EI, Carlile DJ, Chenery R, Houston JB. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. J Pharmacol Exp Ther 1995; 274(2): 761-766.
82. Zomorodi K, Carlile DJ, Houston JB. Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. Xenobiotica 1995; 25(9):907-916.
83. Carlile DJ, Stevens AJ, Ashforth EI, Waghela D, Houston JB. In vivo clearance of ethoxycoumarin and its prediction from in vitro systems. Use of drug depletion and metabolite formation methods in hepatic microsomes and isolated hepatocytes. Drug Metab Dispos 1998; 26(3):216-221.
84. Worboys PD, Bradbury A, Houston JB. Kinetics of drug metabolism in rat liver slices. Rates of oxidation of ethoxycoumarin and tolbutamide, examples of high- and low-clearance compounds. Drug Metab Dispos 1995; 23(3):393-397.
85. Worboys PD, Bradbury A, Houston JB. Kinetics of drug metabolism in rat liver slices. II. Comparison of clearance by liver slices and freshly isolated hepatocytes. Drug Metab Dispos 1996; 24(6):676-681.
86. Worboys PD, Bradbury A, Houston JB. Kinetics of drug metabolism in rat liver slices. III. Relationship between metabolic clearance and slice uptake rate. Drug Metab Dispos 1997; 25(4):460-467.
87. Worboys PD, Brennan B, Bradbury A, Houston JB. Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition. Xenobiotica 1996; 26(9):897-907.
88. Carlile DJ, Hakooz N, Bayliss MK, Houston JB. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol 1999; 47(6):625-635.
89. Witherow LE, Houston JB. Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. J Pharmacol Exp Ther 1999; 290(1):58-65.
90. Kuhnz W, Gieschen H. Predicting the oral bioavailability of 19-nortestosterone progestins in vivo from their metabolic stability in human liver microsomal preparations in vitro. Drug Metab Dispos 1998; 26(11):1120-1127.
91. Van Breeman RB, Nikolic D, Bolton JL. Metabolic screening using on-line ultrafiltration mass spectrometry. Drug Metab Dispos 1998; 26(2):85-90.
92. Rees SA. Bioanalytical strategies to support a discovery research programme. J Pharm Biomed Anal 1996; 14:1185-1190.
93. Fernandez-Metzler CL, Owens KG, Baillie TA, King RC. Rapid liquid chromatography with tandem mass spectrometry-based screening procedures for studies on the biotransformation of drug candidates. Drug Metab Dispos 1999; 27(1):32-40.
94. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. J Am Med Assoc 1993; 269:1513-1518.
95. Guidance for Industry Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro. DHHS, USFDA, Center for Drug Evaluation and Research, April 1997.
96. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998; 55(2):113-122.
97. Crespi CL, Miller VP, Penman BW. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 1997; 248:188-190.
98. Newton DJ, Wang RW, Lu AYH. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23(1):154-158.
99. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996; 26(7):681-693.
100. Hickman D, Wang J-P, Wang Yi, Unadkat J. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 1998; 26(3):207-215.
101. Chauret N, Gauthier A, Nicoll-Griffith DA. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 1998; 26(1):1-4.
102. Eagling VA, Tjia JF, Back DJ. Different selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Pharmacol 1998; 45:107-114.
103. Busby WF, Ackerman JM, Crespi CL. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 1999; 27(2):246-249.
104. Rodrigues AD. Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective. Pharmacol Res 14(11):1504-1510.
105. Tarbit MH, Berman J. High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. Curr Opin Chem Biol 1998; 2:411-416.
106. Chiu S-HL, Thompson KA, Vincent SH, Alvaro RF, Huskey S-EW, Stearns RA, Pettibone DJ. The role of metabolism in drug discovery: a case study in the selection of an oxytocin receptor antagonist for development. Toxicol Pathol 1995; 23(2):124-130.
107. Lin JH, Ostovic D, Vacca JP. The integration of medicinal chemistry, drug metabolism, and pharmaceutical research and development in drug discovery and development. In: Borchardt R, et al., eds. Integration of Pharmaceutical Discovery and Development: Case Studies. New York: Plenum Press, 1998:233-255.
108. Lesko L. The biopharmaceutics classification system: rational use in new drug development and scientific applications in regulatory decision making. Proceedings of the Second Annual Land O' Lakes Drug Metabolism Meeting, Merrimac, WI, USA, 1999.
109. Phillips JC, Gibson WB, Yam J, Alden CL, Hard GC. Survey of the QSAR and in vitro approaches for developing non-animal methods to supersede the in vivo LD50 test. Fd Chem Toxicol 1990; 28(5):375-394.
110. The Johns Hopkins Center for Alternatives to Animal Testing. Cell culture systems and in vitro toxicity testing. Cytotechnology 1992; 8:129-176.
111. Palmer AK. Introduction to (pre)screening methods. Reprod Toxicol 1993; 7:95-98.
112. Bass R. In vitro methods in regulatory toxicology. In: Toxicology in Transition. Proceedings of the 1994 EUROT OX Congress, Basel, Switzerland, August 1994:21-24.
113. Dean JH, Olson HM. The integration of investigative toxicology in the drug discovery process. Biol Cell 1993; 77:58-66.
114. Davila JC, Rodriguez RJ, Melchert RB, Acosta D Jr. Predictive value of in vitro model systems in toxicology. Ann Rev Pharmacol Toxicol 1998; 38:63-96.
115. Timbrell JA. Biomarkers in toxicology. Toxicology 1998; 129:1-13.
116. Todd MD, Ulrich RG. Emerging technologies for accelerated toxicity evaluation of potential drug candidates. Curr Opin Drig Disc Dev 1999; 2(1):58-68.
117. Rogiers V, Vercruysse A. Hepatocyte cultures in drug metabolism and toxicological research and testing. In: Phillips IR, Shephard EA, eds. Methods in Molecular Biology. Vol. 107: Cytochrome P450 Protocols. Tolowa, NJ: Humana Press, 1998.
118. Rahn CA, Bombeck DW, Doolittle DJ. Assessment of mitochondrial membrane potential as an indicator of cytotoxicity. Fund Appl Toxicol 1991; 16:435-448.
119. Kerns EH, Di L. Pharmaceutical profiling in drug discovery. Drug Disc Today 2003; 8:316-323.
120. Eddershaw PJ, Beresford AP, Bayliss MK. ADME/PK as part of a rational approach to drug discovery. Drug Disc Today 2000; 5:409-414.